An ISO9001 Certified Supplier of Pharmaceutical Ingredients and Specialty Chemicals

FLYRCADO®

Drug Information Related Patent
Hold Company
GE HLTHCARE
Learn More
Dosage and Administration
SOLUTION;INTRAVENOUS
Specification
5-55mCi/ML
Indication
Flyrcado® is indicated for positron emission tomography (PET) myocardial perfusion imaging (MPI) under rest or stress (pharmacologic or exercise) in adult patients with known or suspected coronary artery disease (CAD) to evaluate for myocardial ischemia and infarction.
Use
Instructions for Use
API
FLURPIRIDAZ F-18
API Structure
We Supply
FLURPIRIDAZ F 18
Drug Patent
Patent NoExpiration Date
73447022026/5/26
82269292028/6/21
89367772031/6/30
91619972026/2/4
96039512031/5/2
96875712032/11/1
API Patent
Patent NoExpiration Date
73447022026/5/26
82269292028/6/21
91619972026/2/4

Note: The patent information provided herein is derived solely from publicly available data in the FDA Orange Book (or other cited sources) and is presented for general informational purposes only. Actual patent status may vary based on jurisdictional rulings, regulatory extensions or other factors.

HOURS

Daily: 9.30 AM–6.00 PM
Sunday : 9.30 AM–1.00 PM
Holidays: Closed

INFORMATION
CONTACT US
  • Tel:
  • E-mail:
  • Address:
  • WhatsAPP
    WhatsAPP
Privacy Policy | Cookie Policy
Copyright © Protheragen. All Rights Reserved.
Member of
dcat
CERTIFICATION
dcat
dcat dcat dcat dcat
Top